Communication Needed To Avoid Biosimilar ‘Nocebo’ Effect

Enhanced Communication Strategies Show Improvement In Patient Experience

 
• By Dave Wallace

Effective communication between doctors and patients when switching from a branded biologic to a biosimilar is needed to overcome the potential ‘nocebo’ effect, insisted Professor Fabrizio Benedetti at a EULAR symposium.

Doctor - patient
Effective communication with patients is needed to overcome the ‘nocebo’ effect for biosimilars • Source: Shutterstock

More from Biosimilars

More from Products